血管造影衍生血流储备分数与血管内超声指导经皮冠状动脉介入治疗(FLAVOUR II):多中心、随机、非劣效性试验
FLAVOUR II为研究者发起的开放标签多中心随机非劣效性试验,在中国22个中心纳入1872例冠脉造影目测至少50%狭窄且血管直径≥2.5 mm的患者,1:1随机接受血管造影衍生FFR或血管内超声指导PCI(包括血运重建决策和支架优化)。主要终点为12个月死亡、心肌梗死或血运重建的复合终点,非劣效界值2.5个百分点。血管造影衍生FFR组主要终点事件6.3%,血管内超声组6.0%,绝对差0.2个百分点(单侧97.5%CI上限2.4),非劣效性P=0.022;两组死亡率无显著差异。作者认为血管造影衍生FFR指导的综合PCI策略非劣效于血管内超声指导,可能对未来指南产生影响。
要点
- 血管造影衍生FFR组12个月主要终点(死亡、心肌梗死或血运重建)6.3%,血管内超声组6.0%,绝对差0.2个百分点(单侧97.5%CI上限2.4),达到非劣效(P=0.022)。
- 血管造影衍生FFR组血运重建比例69.5%(688/990靶血管),血管内超声组81.0%(797/984靶血管)。
- 两组死亡率无显著差异:血管造影衍生FFR组1.8%,血管内超声组1.3%,绝对差0.4个百分点(95%CI -0.7至1.6),HR 1.34(95%CI 0.63至2.83),P=0.45。
- 复发心绞痛发生率低:血管造影衍生FFR组2.8%(26/923),血管内超声组3.8%(35/916)。
- 研究纳入冠脉造影目测至少50%狭窄且参考血管直径≥2.5 mm的18岁以上疑似缺血性心脏病患者,两种指导方式不允许同时使用。
适用人群与场景
- 年龄18岁及以上、疑似缺血性心脏病、冠脉造影目测心外膜冠状动脉至少50%狭窄且血管直径至少2.5 mm的患者。
- 研究在中国22个中心开展,纳入接受PCI的患者。
诊断标准与关键阈值
- 冠脉造影目测心外膜冠状动脉狭窄至少50%且参考血管直径至少2.5 mm。
- 非劣效界值为2.5个百分点。
处置流程与药物剂量
- 血管造影衍生FFR组:基于预设PCI标准与最佳PCI目标,用血管造影衍生FFR指导血运重建决策和支架植入优化。
- 血管内超声组:基于预设PCI标准与最佳PCI目标,用血管内超声指导血运重建决策和支架植入优化。
- 不允许同时使用两种指导方式。
研究设计与关键结果
- 研究类型:研究者发起的开放标签多中心随机非劣效性试验,中国22个中心,纳入1872例患者,随机分组前33例退出,最终血管造影衍生FFR组923例、血管内超声组916例。
- 人群基线:中位年龄66.0岁(IQR 58.0-72.0),男性1248例(67.9%),女性591例(32.1%)。
- 干预与对照:血管造影衍生FFR指导PCI vs 血管内超声指导PCI,均包括血运重建决策和支架优化。
- 主要终点(12个月死亡、心肌梗死或血运重建复合终点,意向治疗人群):血管造影衍生FFR组56例(6.3%)vs 血管内超声组54例(6.0%),绝对差0.2个百分点(单侧97.5%CI上限2.4),非劣效性P=0.022;HR 1.04(95%CI 0.71至1.51)。
- 关键次要终点:死亡率血管造影衍生FFR组1.8% vs 血管内超声组1.3%,绝对差0.4个百分点(95%CI -0.7至1.6),HR 1.34(95%CI 0.63至2.83),P=0.45。
- 复发心绞痛:血管造影衍生FFR组26/923(2.8%)vs 血管内超声组35/916(3.8%)。
- 血运重建比例:血管造影衍生FFR组688/990靶血管(69.5%)vs 血管内超声组797/984靶血管(81.0%)。
证据类型、等级与局限
- 证据类型:多中心随机非劣效性试验(RCT)。
- 非劣效性检验达到预设界值(P=0.022)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,血管造影衍生FFR指导的综合PCI策略(涵盖血运重建决策和支架优化)非劣效于血管内超声指导,这一发现可能对未来指南中其作用和应用产生影响。
指南或共识出处
- FLAVOUR II试验,注册号ClinicalTrials.gov NCT04397211,发表于Lancet。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Revascularisation decisions based on angiography-derived fractional flow reserve (FFR) or optimisation of stent implantation with intravascular ultrasound yield superior clinical outcomes compared with percutaneous coronary intervention (PCI) guided by angiography alone. However, the differences in outcomes when a single approach is used for both purposes remain unclear. We aimed to assess the non-inferiority of angiography-derived FFR versus intravascular ultrasound guidance in terms of clinical outcomes at 12 months in patients with angiographically significant stenosis.
METHODS: This investigator-initiated, open-label, multicentre, randomised, non-inferiority trial, which was done in 22 centres in China, enrolled patients aged 18 years or older with suspected ischaemic heart disease and with at least 50% stenosis in epicardial coronary arteries measuring at least 2·5 mm by visual estimation on coronary angiography. Patients were randomly assigned (1:1) to undergo PCI guided by either angiography-derived FFR or intravascular ultrasound, including revascularisation decisions and optimisation of the stent implantations based on prespecified PCI criteria and optimal PCI goals. Use of both modalities simultaneously was not permitted. Randomisation as performed using a web-based program and stratified based on the trial centre and the presence or absence of diabetes. The primary outcome was a composite of death, myocardial infarction, or revascularisation at 12 months in the intention-to-treat population, and the non-inferiority margin was 2·5 percentage points. This trial is registered with ClinicalTrials.gov, NCT04397211; long-term follow-up is ongoing.
FINDINGS: Between May 29, 2020, and Sept 20, 2023, 1872 patients were enrolled. After 33 patients withdrew, 923 patients were randomly assigned to the angiography-derived FFR group and 916 to the intravascular ultrasound group. Median age of the study population was 66·0 years (IQR 58·0-72·0), and 1248 (67·9%) patients were male and 591 (32·1%) were female. Revascularisation was performed in 688 (69·5%) of 990 target vessels in the angiography-derived FFR group and 797 (81·0%) of 984 target vessels in the intravascular ultrasound group. At a median follow-up of 12 months (IQR 12-12), the primary outcome event occurred in 56 patients in the angiography-derived FFR group and 54 patients in the intravascular ultrasound group (6·3% vs 6·0%, absolute difference 0·2 percentage points [upper boundary of one-sided 97·5% CI 2·4], pnon-inferiority=0·022; hazard ratio 1·04 [95% CI 0·71 to 1·51]). Mortality did not differ between the two groups (1·8% in the angiography-derived FFR group vs 1·3% in the intravascular ultrasound group, absolute difference 0·4 percentage points [95% CI -0·7 to 1·6]; hazard ratio 1·34 [0·63 to 2·83], p=0·45). The incidence of recurrent angina was low in both groups: 26 (2·8%) of 923 patients in the angiography-derived FFR group and 35 (3·8%) of 916 patients in the intravascular ultrasound group.
INTERPRETATION: The angiography-derived FFR-guided comprehensive PCI strategy, encompassing revascularisation decision making and stent optimisation, was non-inferior to intravascular ultrasound guidance. This finding might have implications for future guidelines on its role and application.
FUNDING: National Natural Science Foundation of China, The Key R & D Projects of Zhejiang Province, and the RCT Program from The Second Affiliated Hospital of Zhejiang University School of Medicine.
参考来源
- Hu X, Zhang J, Yang S, et al. Angiography-derived fractional flow reserve versus intravascular ultrasound to guide percutaneous coronary intervention in patients with coronary artery disease (FLAVOUR II): a multicentre, randomised, non-inferiority trial. Lancet. 2025. PMID: 40174597. doi:10.1016/S0140-6736(25)00504-5
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。